Change from CCR5 to CXCR4 phenotype may affect immunologic responses
9 January 2002. Related: Conference reports.
Conference reports
ddI EC (Videx) study confirms and clarifies dosing on an empty stomach
9 January 2002. Related: Conference reports, Antiretrovirals.
Swatch study: should we be cycling drugs?
9 January 2002. Related: Conference reports, Antiretrovirals.
New HIV drugs, resistance, pharmacogenomics
9 January 2002. Related: Conference reports, Antiretrovirals.
Antiretroviral therapy
9 January 2002. Related: Conference reports, Antiretrovirals.
Immunopathogenesis of HIV infection
9 January 2002. Related: Conference reports.
3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Athens, 23-26 October 2001
9 December 2001. Related: Conference reports.
Insulin resistance
9 December 2001. Related: Conference reports.
Thyroid function abnormalities
9 December 2001. Related: Conference reports.
Lipodystrophy and metabolic changes in children
9 December 2001. Related: Conference reports, Paediatric care.
Bone studies at lipodystrophy workshop
9 December 2001. Related: Conference reports.
8th European Conference on Clinical Aspects and Treatment of HIV-infection, Athens, 28-31 October 2001
2 November 2001. Related: Conference reports.
HIV drug resistance can develop under HAART at low levels of viraemia
2 November 2001. Related: Conference reports, Drug resistance.
Combinations of lopinavir/r and amprenavir in heavily treatment experienced patients
2 November 2001. Related: Conference reports, PK and drug interactions.
Further reports of benefits of polylactic acid for facial lipoatrophy
2 November 2001. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
GigaHAART study shows benefit of treatment interruption prior to treatment with >7 drugs in highly treatment experienced patients
2 November 2001. Related: Conference reports, Drug resistance.
Tenofovir DF 907 study
2 November 2001. Related: Conference reports, Antiretrovirals.
The Max Cmin 1 trial: indinavir/ritonavir vs. saquinavir/ritonavir
2 November 2001. Related: Conference reports, Antiretrovirals.
No significant drug interactions found between tenofovir DF and indinavir, lopinavir/r, lamivudine, or efavirenz
2 November 2001. Related: Conference reports, PK and drug interactions.
Ritonavir corrects drug interaction between efavirenz and saquinavir
2 November 2001. Related: Conference reports, PK and drug interactions.
Lopinavir/r effective in naive patients after three years of treatment
2 November 2001. Related: Conference reports.
1st IAS Conference on HIV Pathogenesis and Treatment, July 8-11 2001, Buenos Aires, Argentina
1 September 2001. Related: Conference reports.
Lipodystrophy and metabolic complications
1 September 2001. Related: Conference reports, Side effects.
Lipodystrophy and metabolic disturbances
1 September 2001. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Pharmacology at 1st IAS
1 September 2001. Related: Conference reports, PK and drug interactions.
Drug-drug interactions
1 September 2001. Related: Conference reports, PK and drug interactions.
Entry inhibitor updates from the 1st IAS
1 September 2001. Related: Conference reports, Antiretrovirals.
Structured treatment interruptions (STIs) and structured intermittent therapy (SITs)
1 September 2001. Related: Conference reports.
Adverse events with antiretrovirals
1 September 2001. Related: Conference reports, Side effects.
5th International Workshop on HIV Drug Resistance, 4-8 June 2001, Scottsdale, Arizona
30 July 2001. Related: Conference reports.
Anti-HIV immune responses and partial viral suppression
30 July 2001. Related: Conference reports, Drug resistance.
HIV resistance, phenotypic drug susceptibility and viral fitness
30 July 2001. Related: Conference reports, Drug resistance.
SWATCH – alternating antiretroviral regimens
30 July 2001. Related: Conference reports, Drug resistance.
Structured treatments interruptions
30 July 2001. Related: Conference reports, Drug resistance.
Importance of additional active drugs for NNRTI-naive patients using NNRTI-based salvage regimens
30 July 2001. Related: Conference reports, Drug resistance.
NNRTI and PI drug plasma levels are as critical as drug sensitivity in achieving treatment success in antiretroviral experienced patients
30 July 2001. Related: Conference reports, Drug resistance.
Increased prevalence of transmission of drug resistant HIV and reduced response in newly infected subjects in nine US cities
30 July 2001. Related: Conference reports, Drug resistance.
Role of codon-69 variants in reduced susceptibility to nucleoside analogues
30 July 2001. Related: Conference reports, Drug resistance.
Selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug naive people
30 July 2001. Related: Conference reports, Drug resistance.
Nucleoside resistance pathways may differ between HIV-1 and HIV-2
30 July 2001. Related: Conference reports, Drug resistance.
Role of Y318F mutation in NNRTI resistance
30 July 2001. Related: Conference reports, Drug resistance.
4th International Conference on Nutrition and HIV Infection and the 2nd European Workshop on Lipodystrophy, April 19-21, 2001, Cannes, France
30 June 2001. Related: Conference reports.
4th International Conference on Nutrition and HIV Infection and the 2nd European Workshop on Lipodystrophy – pt 2
30 June 2001. Related: Conference reports.
Keystone Symposium on HIV, March 28-April 3, Keystone, Colorado: more than one way to skin a virus: innate immune factors that suppress HIV replication
30 June 2001. Related: Conference reports.
2nd International workshop on Clinical Pharmacology of HIV Therapy, 2-4 April, Noordwijk, The Netherlands
17 May 2001. Related: Conference reports.
First randomised trial shows clinical benefit of TDM for people using nelfinavir or indinavir containing combinations
17 May 2001. Related: Conference reports, Antiretrovirals.
Clinical Pharmacology of Antiretroviral Therapy, Liverpool, UK , March 2001
17 May 2001. Related: Conference reports.
8th Conference on Retroviruses and Opportunistic Infections
17 April 2001. Related: Conference reports.
Paediatric treatment issues at the 8th CROI
17 April 2001. Related: Conference reports, Paediatric care, Drug resistance.
8th Conference on Retroviruses and Opportunistic Infections, February 4-8 2001, Chicago, USA
17 March 2001. Related: Conference reports.
From talk to action in fighting AIDS in the developing countries: 8th Retrovirus Conference opening session
17 March 2001. Related: Conference reports, Treatment access.
Differentiating within and between drug classes: sometimes it’s toxicity, sometimes its efficacy
17 March 2001. Related: Conference reports, Antiretrovirals.
Intermittent versus continuous HAART
17 March 2001. Related: Conference reports.
Viral load “blips” and eventual rebound
17 March 2001. Related: Conference reports.
Interaction between garlic and saquinavir and underreporting of alternative treatment use
17 March 2001. Related: Conference reports, PK and drug interactions.
Solid organ transplant in HIV/hepatitis co-infected patients
17 March 2001. Related: Conference reports, Hepatitis coinfection.
HIV and women – overview
17 March 2001. Related: Conference reports, Women's health, Pregnancy.
Update on HIV drug resistance
17 March 2001. Related: Conference reports, Drug resistance.
Update and review of bone studies
17 March 2001. Related: Conference reports.
Treatment interruptions, structured and unplanned, immunotherapy and what’s in store
17 March 2001. Related: Conference reports.
Primary infection and treatment issues
17 March 2001. Related: Conference reports.
Fifth International Congress on Drug Therapy in HIV Infection, 22-26 October 2000, Glasgow, UK
17 December 2000. Related: Conference reports.
Treatment strategies in 2000: planning first-line (and therefore, second-line) therapy
17 December 2000. Related: Conference reports.
When should HAART be started?
17 December 2000. Related: Conference reports.
MDR resistance transmission increases in the UK
17 December 2000. Related: Conference reports, Drug resistance.